Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386581 | 0.99 | — | — | |
| SCHEMBL382831 | 0.81 | — | — | |
| SCHEMBL27224621 | 0.80 | — | — | |
| SCHEMBL27766224 | 0.78 | — | — | |
| SCHEMBL6543142 | 0.78 | NR5A2 (0.30) | — | |
| SCHEMBL28662481 | 0.78 | SLC6A2 (0.31) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14150161 | 0.75 | — | — | |
| SCHEMBL22750238 | 0.74 | OPRK1 (0.30) | — | |
| SCHEMBL30523299 | 0.69 | KDM4E (0.33) | — | |
| SCHEMBL28344710 | 0.66 | OPRL1 (0.37) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327355-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-10-03 | — | — | US | claimed |
| EP-4375273-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | claimed |
| CN-117677607-A | Process for producing aryl amide derivative | 中外制药株式会社 | 2024-03-08 | — | — | CN | claimed |
| WO-2023003014-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | 中外製薬株式会社 | 2023-01-26 | — | — | WO | claimed |
| EP-4741400-A1 | MULTIMERIC MANGANESE CONTRAST AGENTS | Bayer Aktiengesellschaft (DE) | 2026-05-13 | — | — | EP | disclosed |
| US-12590089-B2 | Processes for preparing toll-like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4676547-A2 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4676922-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | SOLEY THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4619387-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12410196-B2 | Benzopyrimidine compounds and use thereof | USYNOVA PHARMACEUTICALS LTD. (CN) | 2025-09-09 | — | — | US | disclosed |
| WO-2003101601-A2 | CROSS-COUPLING SYNTHESIS OF ALKYL (DIALKYLPHENYL) INDENES | BOULDER SCIENTIFIC COMPANY (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003076398-A2 | PYRROLE-2, 5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-09-18 | — | — | WO | disclosed |
| EP-1276726-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | disclosed |
| EP-1254124-A1 | DIPEPTIDE NITRILE CATHPSIN K INHIBITORS | Novartis AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| WO-2002079207-A2 | TRI-AND BIDENTATE AMIDO LIGANDS PREPARED BY PALLADIUM0 COUPLING AND METALLATION THEREOF TO FORM METAL-AMIDO CATALYSTS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-10-10 | — | — | WO | disclosed |
| CN-1336912-A | Novel propargylether derivatives | SINGTENTA PARTICIPATION AG (CH) | 2002-02-20 | — | — | CN | disclosed |
| WO-2001081316-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001058886-A1 | DIPEPTIDE NITRILE CATHEPSIN K INHIBITORS | NOVARTIS AG (CH) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590089-B2 | Processes for preparing toll-like receptor modulator compounds | TLR8, MYD88, TLR6 | SLC6A2 4105/4885SLC6A4 4114/4885SLC6A3 3092/4885 |
| US-12465603-B2 | Phthalazinone based modulators for the treatment of disease | MKI67, BCL2, CCAR2 | SLC6A2 4369/4885SLC6A4 4640/4885SLC6A3 4517/4885 |
| US-20260027113-A1 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | NCOR1, NOP56, NCOR2 | SLC6A2 3843/4885SLC6A4 4306/4885SLC6A3 3853/4885 |
| US-12410196-B2 | Benzopyrimidine compounds and use thereof | DPYD, CYP2D6, TYMP | SLC6A2 1730/4885SLC6A4 1727/4885SLC6A3 2452/4885 |
| US-20240327355-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | BRAF, RAF1, NRAS | SLC6A2 3823/4885SLC6A4 3999/4885SLC6A3 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.